**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 53581

**Manuscript Type:**ORIGINAL ARTICLE

***Case Control Study***

**Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf related protein-1 in ankylosing spondylitis**

Xiong JH *et al*. DKK-1 and TNF-α in ankylosing spondylitis

Jun-Hui Xiong, Jian Liu, Jian Chen

**Jun-Hui Xiong, Jian Liu, Jian Chen,** Department of Rheumatology, Lishui People’s Hospital, Lishui 323000, Zhejiang Province, China

**Author contributions:** Xiong JH contributed to the study design and reviewed the manuscript; Liu J analyzed the data and contributed to manuscript writing; Xiong JH and Chen J contributed to data collection, data interpretation and manuscript writing; All authors read and approved the final manuscript.

**Corresponding author:** **Jian Chen, BSc, Attending Doctor,** Department of Rheumatology, Lishui People’s Hospital, No. 15 Dazhong Street, Liandu District, Lishui 323000, Zhejiang Province, China. cairuke99@163.com

**Received:** December 25, 2019

**Revised:** March 2, 2020

**Accepted:**March 19, 2020

**Published online:**

Abstract

BACKGROUND

Ankylosing spondylitis (AS) frequently occurs in people aged 30-45 years, and its prevalence is generally believed to be between 0.1% and 1.4% globally. At present, the “gold standard” for diagnosis of AS requires the provision of pelvic X-rays, which makes it more difficult to perform in population-based epidemiological studies. Therefore, the identification of serological indicators related to the diagnosis, treatment, and prognosis of AS patients is of great significance.

AIM

To analyze the therapeutic, diagnostic significance and prognostic value of dickkopf-related protein-1 (DKK-1) and tumor necrosis factor-α (TNF-α) in AS.

METHODS

A total of 113 patients with active AS were selected as the research group, and 100 healthy subjects who underwent physical examination were selected as the control group. The levels of DKK-1 and TNF-α in peripheral blood in the two groups were compared. The diagnostic and predictive values of DKK-1 and TNF-α for AS were analyzed with ROC curves, and the factors influencing AS recurrence were analyzed with COX regression.

RESULTS

Before treatment, the research group showed lower DKK-1 levels but higher TNF-α levels than the control group (both a*P* < 0.05). In the research group, DKK-1 was up-regulated and TNF-α was down-regulated after 12 wk of treatment (a*P* < 0.05). The area under the curve, sensitivity and specificity of DKK-1 combined with TNF-α for diagnosing AS were 0.934, 82.30% and 97.00%, respectively. Before treatment, the area under the curve, cutoff value, sensitivity and specificity of DKK-1 for predicting the curative effect were 0.825, 68.42 pg/mL, 73.68% and 80.00%, respectively, and those of TNF-α were 0.863, 32.79 ng/L, 92.11% and 77.33%, respectively. DKK-1 and TNF-α levels after treatment were closely related to the curative effect (a*P* < 0.05). C-reactive protein, the Bath Ankylosing Spondylitis Disease Activity Index, DKK-1, and TNF-α were risk factors for AS recurrence (a*P* < 0.05).

CONCLUSION

DKK-1 and TNF-α are effective in the diagnosis and treatment of AS and are risk factors for its recurrence. In addition, DKK-1 may be a potential target for the diagnosis of AS.

**Key words:** Dickkopf-related protein-1; Tumor necrosis factor-α; Ankylosing spondylitis; Diagnosis; Prognosis; Peripheral blood

Xiong JH, Liu J, Chen J. Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf-related protein-1 in ankylosing spondylitis. *World J Clin Cases* 2020; In press

**Core tip:** In this study, we demonstrated that dickkopf-related protein-1 and tumor necrosis factor-α are effective in the diagnosis and treatment of ankylosing spondylitis and are risk factors for its recurrence. In addition, dickkopf-related protein-1 may be a potential target for future treatment of ankylosing spondylitis.

INTRODUCTION

Ankylosing spondylitis (AS) is an inflammatory arthritis within a family of disorders including reactive arthritis, inflammatory bowel disease-associated spondyloarthritis (SpA), and undifferentiated spondyloarthritis (uSpA)[1], which is common in people aged 30-45 years old. The prevalence of AS is generally believed to be between 0.1% and 1.4% globally[2]. At present, the “gold standard” for diagnosis of AS is the modified New York criteria[3]. However, these criteria require the provision of pelvic X-rays, which are more difficult to perform in population-based epidemiological studies. In addition, the prognosis of patients with AS is variable and closely related to extraspinal manifestations (such as uveitis, psoriasis and inflammatory bowel disease), age at diagnosis and treatment. AS often severely impairs spinal mobility and body function, and affects the quality of life of patients[4,5]. Therefore, the identification of serological indicators related to the treatment, diagnosis and prognosis is of great significance for AS screening.

Dickkopf-related protein-1 (DKK-1) is a natural inhibitor of the Wnt signaling pathway, and Wnt controls osteoblastogenesis and is the key to ectopic bone formation[6]. Increased DKK-1 level is related to bone resorption, while a decreased level is related to new bone formation[7,8]. There is evidence that dysfunctional DKK-1 in AS reduces its inhibition on the Wnt signaling pathway, and is related to the functional dominance of circulating bone formation–promoting factors[9]. The correlation between tumor necrosis factor α (TNF-α) and AS has been widely studied, and anti-TNF-α therapy has also been reported to play a role in the treatment of AS[10,11]. Therefore, DKK-1 and TNF-α may have potential in the diagnosis and treatment of AS, providing an objective and convenient index. This study examined the therapeutic, diagnostic significance and prognostic value of DKK-1 and TNF-α in AS to provide references for the diagnosis and treatment of AS.

**MATERIALS AND METHODS**

***Research subjects***

A total of 113 patients with active AS admitted to Lishui People’s Hospital from October 2015 to July 2017 were selected as the research group, and 100 healthy subjects who underwent physical examination in Lishui People’s Hospital during the same period were enrolled as the control group. Patients in both groups were aged 30-45 years. Inclusion criteria were as follows: patients in the research group meeting the modified New York criteria for AS revised in 1984[3], and treated according to the guidelines[12] formulated by the American College of Rheumatology, the American Spondylitis Association, and the Spondyloarthritis Research and Treatment Network in 2015; patients with complete medical records and follow-up data; controls with no obvious clinical symptoms related to spinal or joint lesions. The study followed the principle of the “Helsinki Declaration”. Exclusion criteria were as follows: patients with non-radiographic Axial SpA; patients in the research group with comorbid rheumatoid diseases, intervertebral disc herniation, peripheral arthritis and other joint diseases; patients with mental diseases; pregnant or lactating women. This study was approved by the Lishui People’s Hospital Ethics Committee. Patients and their families were consulted by telephone or letter and signed an informed consent form.

***Outcome measures***

Basic information such as sex and age were collected from clinical medical records. After 12 wk of treatment, the therapeutic effect was assessed by the Assessment in Ankylosing Spondylitis 20% (ASAS20) criteria developed by the ASAS International Society[13]. The levels of DKK-1 and TNF-α in peripheral blood in the two groups were compared, and the correlations of DKK-1 and TNF-α with AS-related indices were analyzed. ROC analysis was used to analyze the diagnostic and predictive value of DKK-1 and TNF-α in AS, and COX regression was used to analyze the factors influencing AS recurrence. During follow-up, patients with a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 3.5 and BASDAI scores exceeding 60% of the baseline value were considered to have recurrence.

***Detection methods***

Peripheral blood from all subjects was obtained by nurses in Lishui People’s Hospital before and 12 wk after treatment, and DKK-1 and TNF-α were quantified by enzyme linked immunosorbent assay (ELISA). The specific method used was in accordance with the kit instructions. The detection kits were purchased from Abcam Company, United States, with the article numbers ab100501 and ab181421.

***Statistical analysis***

Statistical analysis was carried out with SPSS 19.0 (Asian Analytics Formerly SPSS China). The counting data were expressed as percentage (%), and the comparison adopted *χ*2 test. The measurement data were expressed as mean ± sd and analyzed by the Students' *t* test. The ROC curve was applied to analyze the diagnostic and predictive value of DKK-1 and TNF-α in AS, and COX regression was used to analyze the factors influencing the recurrence of AS. A correlation analysis was performed with Spearman and Pearson tests. A value of a*P* < 0.05 indicated statistical significance.

**Results**

***General information***

There were 113 patients in the research group, including 76 males and 37 females, aged (36.7 ± 4.1) years, and 100 subjects in the control group, including 76 males and 24 females, aged (37.3 ± 4.6) years. There were no significant differences in sex ratio and age between the two groups (Table 1).

***Difference in DKK-1 expression between the two groups***

Before treatment, the research group showed lower DKK-1 levels than the control group (a*P* < 0.05). After treatment, the level of DKK-1 in the research group was higher than that before treatment (a*P* < 0.05). Correlation analysis showed that the expression of DKK-1 was significantly correlated with C-reactive protein (CRP), Immunoglobulin G (IgG), IgA, IgM, Human leukocyte antigen B27 (HLA-B27), erythrocyte sedimentation rate (ESR), BASDAI and Bath Ankylosing Spondylitis Metrology Index (BASMI) (a*P* < 0.05), but was not correlated with human leukocyte antigen-B27 (HLA-B27) (Figure 1).

***Difference in TNF-α expression in the two groups***

Before treatment, the research group showed higher TNF-α levels than the control group (a*P* < 0.05). After treatment, the level of TNF-α in the research group was lower than that before treatment (a*P* < 0.05) (Figure 2).

***Diagnostic value of DKK-1 and TNF-α in AS***

The area under the curve (AUC), cutoff value, sensitivity and specificity of DKK-1 for diagnosing AS were 0.752, 87.02 pg/mL, 78.76% and 66.00%, respectively, and those of TNF-α were 0.904, 18.79 ng/L, 79.65% and 95.00%. The AUC, sensitivity and specificity of combined diagnosis were 0.934, 82.30% and 97.00%, respectively (Table 2, Figure 3).

***Relationship between DKK-1, TNF-α and curative effect in AS***

Seventy-five patients met the ASASAS20 criteria (= 2) and 35 patients did not (= 1). The AUC, cutoff value, sensitivity and specificity of DKK-1 in predicting the curative effect in AS before treatment were 0.825, 68.42 pg/mL, 73.68%, and 80.00%, respectively, and those of TNF-α were 0.863, 32.79 ng/L, 92.11% and 77.33%, respectively(Table 3, Figure 4). After treatment, DKK-1 was positively correlated with the curative effect, while TNF-α was negatively correlated with the curative effect (a*P* < 0.05) (Figure 5).

***Influencing factors for AS recurrence***

The patients in the research group were followed up for 9 mo, 80 of whom had recurrent AS, with a recurrence rate of 70.80%. COX analysis showed that CRP, BASDAI, DKK-1, and TNF-α were risk factors for recurrence (a*P* < 0.05) (Table 4).

**DISCUSSION**

AS is a chronic inflammatory disease characterized by new bone formation, which gradually leads to spinal dysfunction[14]. At present, there is no cure for AS, only early diagnosis can improve the prognosis; thus, early diagnosis and prognosis evaluation are of great significance for patients and clinical treatment. This study revealed the high diagnostic and therapeutic value of DKK-1 and TNF-α in AS, and these parameters were found to be associated with AS recurrence.

Our findings suggested that DKK-1 expression decreased in the peripheral blood of patients with AS, while TNF-α expression increased. Moreover, after treatment, DKK-1 correspondingly increased and TNF-α decreased. At present, the relationship between TNF-α and AS is relatively clear, and TNF-α inhibitors are widely applied in the clinical treatment of AS[15,16]. DKK-1 was reported to have decreased expression and disordered function in AS patients, suggesting that DKK-1 is closely related to AS[17,18], which is similar to our results. DKK-1 is a natural inhibitor of the Wnt pathway and inhibits bone formation by inhibiting this pathway. Decreased or dysfunctional DKK-1 may reduce the inhibitory effect on the Wnt pathway, resulting in increased bone formation, which is currently considered to be one of the mechanisms of DKK-1 in AS[19,20]. The diagnostic value of DKK-1 and TNF-α in AS was further analyzed in this study, and it was found that the AUC of DKK-1 in the diagnosis of AS was 0.752, that of TNF-α was 0.904, and that of combined diagnosis reached 0.934, which indicates that DKK-1 combined with TNF-α is effective in the diagnosis of AS. Bal *et al*[21] stated that TNF-α could be used for AS diagnosis, but the specific diagnostic value was not verified. There are few reports on the diagnostic value of DKK-1 and TNF-α in AS; however, DKK-1 has been found to be closely related to the occurrence and development of AS. Wu *et al*[22] reported that DKK-1 was a biomarker of inflammation and radiographic damage in AS. We also found that DKK-1 was significantly linearly correlated with CRP, IgG, IgM, ESR, BASDAI, and BASMI, but the correlation coefficient was insignificant; therefore, further validation in more cases is required. Liao *et* *al*[23] reported that DKK-1 expression was significantly correlated with disease activity, radiological and functional indices in AS patients, which is similar to our findings. The correlation between DKK-1, TNF-α and the therapeutic effect in AS was also analyzed in this study. Before treatment, the AUC of DKK-1 levelfor predicting the curative effect was 0.825, and that of TNF-α was 0.863, suggesting that both DKK-1 and TNF-α have good predictive value for curative effect assessment, which may contribute to the development and improvement of treatment regimens. Moreover, a correlation was observed between DKK-1, TNF-α levels and curative effect after treatment, which verified the relationship between them in AS. Further analysis also found that DKK-1, TNF-α, CRP, and BASDAI were risk factors for AS recurrence. Deng *et al*[24] found that the patient global assessment and CRP can be regarded as predictive factors for the recurrence of AS. Baraliakos *et al*[25] reported that BASDAI, CRP, age and course of disease were related to the recurrence time of AS, which supports our findings. Therefore, DKK-1 and TNF-α are predictors of curative effect and prognostic risk factors of AS.

However, this study also had some shortcomings. Firstly, although we observed a significant correlation between DKK-1 and CRP and ESR in AS patients, it is not known whether the difference in the expression of DKK-1 in AS is affected by inflammation and ESR; thus, this will be investigated in our next study. Secondly, the relationship between DKK-1 and the severity of AS also requires further analysis.

In conclusion, DKK-1 and TNF-α are effective in the diagnosis and treatment of AS and are risk factors for its recurrence. In addition, DKK-1 may be a potential target for future treatment of AS.

**ARTICLE HIGHLIGHTS**

***Research background***

Ankylosing spondylitis (AS) frequently occurs in people aged 30-45 years, and its prevalence is generally believed to be between 0.1% and 1.4% globally. At present, the “gold standard” for diagnosis of AS requires the provision of pelvic X-rays, which makes it more difficult to perform in population-based epidemiological studies. Therefore, the identification of serological indicators related to the diagnosis, treatment, and prognosis of AS patients is of great significance.

***Research motivation***

The “gold standard” for ankylosing spondylitis depends on X-rays, and the prognosis of patients with ankylosing spondylitis is variable and closely related to the patient’s extraspinal manifestations (such as uveitis, psoriasis, and IBD), age at diagnosis, and treatment. The identification of convenient serological indicators related to patient treatment, diagnosis and prognosis is of great significance.

***Research objectives***

This study aimed to analyze the therapeutic, diagnostic significance and prognostic value of Dickkopf-related protein-1 (DKK-1) and tumor necrosis factor-α (TNF-α) in AS.

***Research methods***

A total of 113 patients with active AS were selected as the research group, and 100 healthy subjects who underwent physical examination were selected as the control group. The levels of DKK-1 and TNF-α in peripheral blood in the two groups were compared. The diagnostic and predictive value of DKK-1 and TNF-α for AS were analyzed with ROC curves, and the factors influencing AS recurrence were analyzed with COX regression.

***Research results***

Before treatment, the research group showed lower DKK-1 levels but higher TNF-α levels than the control group (both a*P* < 0.05). In the research group, DKK-1 was up-regulated and TNF-α was down-regulated after 12 wk of treatment (a*P* < 0.05). The (area under the curve) AUC, sensitivity and specificity of DKK-1 combined with TNF-α for diagnosing AS were 0.934, 82.30% and 97.00%, respectively. Before treatment, the AUC, cutoff value, sensitivity and specificity of DKK-1 for predicting the curative effect were 0.825, 68.42 pg/mL, 73.68% and 80.00%, respectively, and those of TNF-α were 0.863, 32.79 ng/L, 92.11% and 77.33%, respectively. DKK-1 and TNF-α levels after treatment were closely related to the curative effect (a*P* < 0.05). C-reactive protein, the Bath Ankylosing Spondylitis Disease Activity Index, DKK-1, and TNF-α were risk factors for AS recurrence (a*P* < 0.05).

***Research conclusions***

DKK-1 and TNF-α are effective in the diagnosis and treatment of AS and are risk factors for its recurrence. In addition, DKK-1 may be a potential target for the diagnosis of AS.

***Research perspectives***

Further analysis of the differential diagnostic value of DKK-1 and TNF-α in AS and suspected AS (such as lumbosacral joint strain, tuberculous spondylitis, Forestier disease, *etc*), and the provision of more evidence for the clinical diagnosis of AS are required.

**REFERENCES**

1 **Dean LE**, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. *Rheumatology (Oxford)* 2014; **53**: 650-657 [PMID: 24324212 DOI: 10.1093/rheumatology/ket387]

2 **Akkoc N**. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. *Curr Rheumatol Rep* 2008; **10**: 371-378 [PMID: 18817640 DOI: 10.1007/s11926-008-0060-3]

3 **Reveille JD**. Epidemiology of spondyloarthritis in North America. *Am J Med Sci* 2011; **341**: 284-286 [PMID: 21430444 DOI: 10.1097/MAJ.0b013e31820f8c99]

4 **Boonen A**, van der Linden SM. The burden of ankylosing spondylitis. *J Rheumatol Suppl* 2006; **78**: 4-11 [PMID: 17042055]

5 **Olivieri I**, van Tubergen A, Salvarani C, van der Linden S. Seronegative spondyloarthritides. *Best Pract Res Clin Rheumatol* 2002; **16**: 723-739 [PMID: 12473270 DOI: 10.1053/berh.2002.0263]

6 **Diarra D**, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. *Nat Med* 2007; **13**: 156-163 [PMID: 17237793 DOI: 10.1038/nm1538]

7 **MacDonald BT**, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV. Bone mass is inversely proportional to Dkk1 levels in mice. *Bone* 2007; **41**: 331-339 [PMID: 17613296 DOI: 10.1016/j.bone.2007.05.009]

8 **Li J**, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. *Bone* 2006; **39**: 754-766 [PMID: 16730481 DOI: 10.1016/j.bone.2006.03.017]

9 **Daoussis D**, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. *Arthritis Rheum* 2010; **62**: 150-158 [PMID: 20039407 DOI: 10.1002/art.27231]

10 **Poddubnyy D**, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years. *J Rheumatol* 2016; **43**: 2142-2148 [PMID: 27803139 DOI: 10.3899/jrheum.160594]

11 **Carbo MJG**, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H, van der Veer E, Wink F, Arends S. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors. *PLoS One* 2018; **13**: e0196281 [PMID: 29689112 DOI: 10.1371/journal.pone.0196281]

12 **Ward MM**, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol* 2016; **68**: 282-298 [PMID: 26401991 DOI: 10.1002/art.39298]

13 **Sieper J**, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis* 2017; **76**: 571-592 [PMID: 27582421 DOI: 10.1136/annrheumdis-2016-210023]

14 **Pelechas E,** Kaltsonoudis E, Voulgari PV, Drosos AA. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Springer Nature Switzerland AG: Springer, 2019: 121-140 [DOI: 10.1007/978-3-030-03664-5]

15 **Maas F**, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, Spoorenberg A. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors. *PLoS One* 2017; **12**: e0177231 [PMID: 28640818 DOI: 10.1371/journal.pone.0177231]

16 **Maas F**, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, Veeger NJ, van Ooijen PM, Wolf R, Bootsma H, van der Veer E, Arends S. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. *PLoS One* 2015; **10**: e0122693 [PMID: 25879956 DOI: 10.1371/journal.pone.0122693]

17 **Huang J**, Song G, Yin Z, Fu Z, Zhang L. Altered expression of microRNAs targeting Dkk-1 in peripheral blood mononuclear cells of patients with ankylosing spondylitis. *Cent Eur J Immunol* 2019; **44**: 59-64 [PMID: 31114438 DOI: 10.5114/ceji.2019.84018]

18 **Zhang L**, Ouyang H, Xie Z, Liang ZH, Wu XW. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. *Exp Mol Med* 2016; **48**: e228 [PMID: 27103566 DOI: 10.1038/emm.2016.12]

19 **Sun W**, Tian L, Jiang L, Zhang S, Zhou M, Zhu J, Xue J. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis. *Clin Rheumatol* 2019; **38**: 989-995 [PMID: 30443790 DOI: 10.1007/s10067-018-4356-z]

20 **Orsolini G**, Adami G, Rossini M, Ghellere F, Caimmi C, Fassio A, Idolazzi L, Gatti D, Viapiana O. Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. *Clin Rheumatol* 2018; **37**: 3093-3098 [PMID: 29995219 DOI: 10.1007/s10067-018-4205-0]

21 **Bal A**, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. *Clin Rheumatol* 2007; **26**: 211-215 [PMID: 16583185 DOI: 10.1007/s10067-006-0283-5]

22 **Wu M**, Chen M, Ma Y, Yang J, Han R, Yuan Y, Hu X, Wang M, Zhang X, Xu S, Liu R, Jiang G, Xu J, Shuai Z, Zou Y, Pan G, Pan F. Dickkopf-1 in ankylosing spondylitis: Review and meta-analysis. *Clin Chim Acta* 2018; **481**: 177-183 [PMID: 29544750 DOI: 10.1016/j.cca.2018.03.010]

23 **Liao HT**, Lin YF, Tsai CY, Chou TC. Bone morphogenetic proteins and Dickkopf-1 in ankylosing spondylitis. *Scand J Rheumatol* 2018; **47**: 56-61 [PMID: 28303752 DOI: 10.1080/03009742.2017.1287305]

24 **Deng X**, Zhang J, Zhang J, Huang F. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. *Rheumatol Int* 2013; **33**: 1409-1413 [PMID: 23143621 DOI: 10.1007/s00296-012-2571-5]

25 **Baraliakos X**, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005; **7**: R439-R444 [PMID: 15899030 DOI: 10.1186/ar1693]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Lishui People’s Hospital Ethics Committee.

**Informed consent statement:** All patients in our study provided informed consent.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data are available.

**STROBE Statement**: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** December 25, 2019

**First decision:** February 20, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cure E, Soriano ER **S-Editor:** Zhang L **L-Editor:** Webster JR **E-Editor:**

**Figure Legends**



**Figure 1 Difference in Dickkopf-related protein-1 expression in the two groups.** A: Difference in dickkopf-related protein-1 (DKK-1) expression between the control group and the research group before treatment; B: Difference in DKK-1 expression before and after treatment in the research group; C: Correlation between DKK-1 and C-reactive protein; D: Correlation between DKK-1 and Immunoglobulin G; E: Correlation between DKK-1 and Immunoglobulin A; F: Correlation between DKK-1 and Immunoglobulin M; G: Correlation between DKK-1 and HLA-B27; H: Correlation between DKK-1 and erythrocyte sedimentation rate; I: Correlation between DKK-1 and the Bath Ankylosing Spondylitis Disease Activity Index; J: Correlation between DKK-1 and the Bath Ankylosing Spondylitis Metrology Index. a*P* < 0.05.



**Figure 2** **Difference in tumor necrosis factor-α expression in the two groups.** A: Difference in tumor necrosis factor-αexpression between the control group and the research group before treatment; B: Difference in tumor necrosis factor-α expression before and after treatment in the research group. a*P* < 0.05. TNF-α: Tumor necrosis factor-α.



**Figure 3** **Diagnostic value of dickkopf-related protein-1 and tumor necrosis factor-α in ankylosing spondylitis.** The area under the curve, cutoff value, sensitivity and specificity of dickkopf-related protein-1 for diagnosing ankylosing spondylitis were 0.752, 87.02 pg/mL, 78.76% and 66.00% respectively, and those of tumor necrosis factor-α were 0.904, 18.79 ng/L, 79.65% and 95.00%. The area under the curve, sensitivity and specificity of combined diagnosis were 0.934, 82.30% and 97.00% respectively. TNF-α: Tumor necrosis factor-α; DKK: dickkopf-related protein-1.

****

**Figure 4 Predictive value of dickkopf-related protein-1 and tumor necrosis factor-α in the curative effect in ankylosing spondylitis.** The area under the curve, cutoff value, sensitivity and specificity of dickkopf-related protein-1 for predicting the curative effect before treatment were 0.825, 68.42 pg/mL, 73.68% and 80.00% respectively, and those of tumor necrosis factor-α were 0.863, 32.79 ng/L, 92.11% and 77.33%, respectively. TNF-α: Tumor necrosis factor-α; DKK: Dickkopf-related protein-1.



**Figure 5 Correlation between dickkopf-related protein-1, tumor necrosis factor-α and the curative effect in ankylosing spondylitis.** A: Correlation between dickkopf-related protein-1 and curative effect in ankylosing spondylitis; B: Correlation between tumor necrosis factor-α and curative effect in ankylosing spondylitis. TNF-α: Tumor necrosis factor-α; DKK: Dickkopf-related protein-1.

**Table 1** **General information**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Study group (*n* = 113)** | **Control group (*n* = 100)** | ***bP* value** |
| Sex, *n* (%) |  |  | 0.159 |
| Male | 76 (67.26) | 76 (76.00) |  |
| Female | 37 (32.74) | 24 (24.00) |  |
| Age (yr) | 36.7 ± 4.1 | 37.3 ± 4.6 | 0.315 |
| BMI (kg/m2) | 22.25 ± 1.83 | 23.49 ± 2.16 | 0.381 |
| Course of disease (yr) | 1.5 ± 0.4 |  |  |
| CRP (ng/L) |  |  |  |
| Before treatment | 8.61 ± 0.72 | 0.50 ± 0.00 | < 0.001 |
| After treatment | 1.32 ± 0.121 |  |  |
| IgG (g/L) |  |  |  |
| Before treatment | 16.00 ± 1.75 |  |  |
| After treatment | 2.89 ± 0.45 1 |  |  |
| IgA (g/L) |  |  |  |
| Before treatment | 4.88 ± 0.91 |  |  |
| After treatment | 0.82 ± 0.21 1 |  |  |
| IgM (g/L) |  |  |  |
| Before treatment | 1.49 ± 0.48 |  |  |
| After treatment | 0.24 ± 0.08 1 |  |  |
| Rheumatoid factor | (-) |  |  |
| HLA-B27 (+), *n* (%) |  |  |  |
| Before treatment | 85 (75.00) | 0 (0.00) | < 0.001 |
| After treatment | 15 (13.27) 1 |  |  |
| ESR (mm/h) |  |  |  |
| Before treatment | 48.83 ± 7.79 | 12.29 ± 2.73 | < 0.001 |
| After treatment | 28.14 ± 4.32 1 |  |  |
| BASDAI |  |  |  |
| Before treatment | 4.98 ± 1.61 |  |  |
| After treatment | 0.93 ± 0.24 1 |  |  |
| BASMI |  |  |  |
| Before treatment | 4.26 ± 1.96 |  |  |
| After treatment | 0.71 ± 0.311 |  |  |

1indicates compared with the research group before treatment. a*P* < 0.05. BMI : Body mass index; CRP: C-reactive protein; IgG: Immunoglobulin G; IgA: Immunoglobulin A; IgM: Immunoglobulin M; HLA-B27: Human leukocyte antigen-B27; ESR: Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASMI: Bath Ankylosing Spondylitis Metrology Index.

**Table** **2** **Diagnostic value of dickkopf-related protein-1 and tumor necrosis factor-α in ankylosing spondylitis by receiver operating characteristic curve**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **DKK-1** | **TNF-α** | **Combination** |
| AUC | 0.752 | 0.904 | 0.934 |
| 95%CI | 0.684-0.820 | 0.859-0.950 | 0.900-0.967 |
| Cutoff value | 87.02 pg/mL | 18.79 ng/L |  |
| Sensitivity | 78.76% | 79.65% | 82.30% |
| Specificity | 66.00% | 95.00% | 97.00% |

TNF-α: Tumor necrosis factor-α; DKK: Dickkopf-related protein-1; AUC: Area under the curve.

**Table 3** **Predictive value of dickkopf-related protein-1 and tumor necrosis factor-α on the curative effect in ankylosing spondylitis by receiver operating characteristic curve**

|  |  |  |
| --- | --- | --- |
|  | **DKK-1** | **TNF-α** |
| AUC | 0.825 | 0.863 |
| 95%CI | 0.749-0.901 | 0.794-0.932 |
| Cutoff value | 68.42 pg/mL | 32.79 ng/L |
| Sensitivity | 73.68% | 92.11% |
| Specificity | 80.00% | 77.33% |

TNF-α: Tumor necrosis factor-α; DKK: Dickkopf-related protein-1; AUC: Area under the curve.

**Table 4** **Multivariate analysis of recurrence of ankylosing spondylitis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | **Wald** | **df** | **Sig.** | **Exp (B)** | **95.0%CI** |
| **Lower part** | **Upper part** |
| TNF-α | -0.450 | 0.362 | 1.549 | 1 | 0.013 | 0.637 | 0.314 | 1.296 |
| CRP | 3.871 | 2.473 | 2.450 | 1 | 0.018 | 47.992 | 0.377 | 61.152 |
| IgG | 0.162 | 0.089 | 3.325 | 1 | 0.168 | 1.176 | 0.988 | 1.445 |
| HLA-B27 | -13.651 | 139.432 | 0.010 | 1 | 0.062 | 1.325 | 0.745 | 3.306 |
| BASDAI | 0.305 | 0.094 | 10.524 | 1 | 0.001 | 1.357 | 1.128 | 1.631 |
| BASMI | -0.063 | 0.071 | 0.79 | 1 | 0.074 | 0.939 | 0.816 | 1.079 |
| DKK-1 | 0.020 | 0.008 | 6.877 | 1 | 0.009 | 1.021 | 1.005 | 1.036 |

TNF-α: Tumor necrosis factor-α; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; CRP: C-reactive protein; IgG: Immunoglobulin G; DKK: Dickkopf-related protein-1.